Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression

People with previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression are asked to participate in a research study being conducted by White Plains Hospital.

You may be eligible to participate in this study if you:

• Are a male or female at least 18 years of age
• Have histologically documented gastric or GEJ adenocarcinoma (not amenable to curative therapy).
• Have disease that is unresectable, locally advanced, or metastatic
• Have adequate organ function

You may NOT participate in this study if you:

• Have Untreated or symptomatic central nervous system (CNS) metastases and leptomeningeal disease
• Have impaired cardiac function or clinically significant cardiac disease
• Have an active infection requiring systemic treatment or any uncontrolled infection
• Have known immunodeficiency virus (HIV) infection, hepatitis B or C
• Have a history of interstitial lung disease
• Have had major surgical procedure within 28 days
• Are pregnant or breastfeeding

Contact Information
Hyemin Kim, Study Coordinator
41 East Post Road, White Plains, New York 10601
Phone: (914) 849-7591
Email: HKIM3@WPHOSPITAL.ORG

21-06-479